Prevalence of human papillomavirus infection among young women in North India |
| |
| Authors: | Palika Datta Neerja Bhatla Lalit Dar A Rajkumar Patro Arti Gulati Alka Kriplani Neeta Singh |
| |
| Affiliation: | 1. Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India;2. Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India;3. Department of Microbiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India;1. National Institute of Biomedical Genomics, P.O.: N.S.S., Kalyani 741251, West Bengal, India;2. Department of Obstetrics & Gynecology, College of Medicine & J.N.M. Hospital, WBUHS, P.O. Kalyani, Nadia 741235, West Bengal, India;1. RTI International India, New Delhi, India;2. International Agency for Research on Cancer, World Health Organization, Lyon, France;3. National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India;4. Department of Health and Family Welfare, Government of Punjab, Chandigarh, India;5. Human Services and Family Welfare Department, Government of Sikkim, Gangtok, India;6. Delhi State Cancer Institute, Delhi, India;7. Prince Aly Khan Hospital, Mumbai, India;8. Tata Trusts, Mumbai, India;9. National Institute of Cancer Prevention and Research, Indian Council of Medical Research, Noida, India;10. National Cancer Institute, All India Institute of Medical Sciences, Jhajjar Campus, Badsa, Haryana, India;11. Dr B R Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India;12. Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi, India;13. Kings Clinical Trials Unit, King''s College London, London, UK;14. King''s Health Partners Integrated Cancer Centre, King''s College London, London, UK;15. Office of Global Affairs, Department of Health and Human Services, Washington, DC, USA;p. Global HPV and Cervical Cancer Research and Control, National Cancer Institute, Rockville, MD, USA;q. World Health Organization, Geneva, Switzerland;1. Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital Premises, 32 Sassoon Road, Pune 411001, India;2. Rajiv Gandhi Centre for Biotechnology, Thycaud PO, Poojappura, Thiruvananthapuram 695014, Kerala, India;3. Prayas Health Group, Amrita Clinic, Athwale Corner, Karve Road, Deccan Gymkhana, Pune, India;4. Screening Group (SCR), Early Detection & Prevention Section (EDP), International Agency for Research on Cancer (WHO-IARC), 150 cours Albert Thomas, 69372 Lyon Cedex 08, France;5. Infections and Cancer Biology Group, Infections Section, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France;1. VCS Population Health, VCS Foundation, Level 6, 176 Wellington Parade, East Melbourne, VIC, 3002, Australia;2. Melbourne School of Population and Global Health, University of Melbourne, Level 3, 207 Bouverie Street, Carlton, Victoria 3053, Australia;3. VCS Pathology, VCS Foundation, 265 Faraday Street, Carlton South, Victoria 3053, Australia;4. Department of Pharmacology and Therapeutics, The University of Melbourne, Victoria 3010, Australia;5. Centre for Women’s Infectious Diseases, The Royal Women’s Hospital, Cnr Grattan St & Flemington Rd, Parkville, Victoria 3052, Australia;6. Infection and Immunity, Murdoch Children’s Research Institute, Parkville, Victoria, Australia;7. Cancer Research Division, Cancer Council NSW, 153 Dowling St, Woolloomooloo, NSW 2011, Australia;8. Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria 3010, Australia;1. International Agency for Research on Cancer, Lyon, France;2. Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program (CERP), Institut Català d’Oncologia - Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain;3. Obstetrics and Gynecology, Gynecologic Oncology, American University of Beirut, Medical Center, Beirut, Lebanon |
| |
| Abstract: | Background: The number of women infected with human papillomavirus (HPV) and the distribution of the HPV genotypes vary across populations and with age. Objective: To determine the prevalence and genotype distribution of HPV in young married women aged 16–24 years. Methods: 1300 women residing in an urban slum in Delhi donated samples of exfoliated cervical cells that were collected by the Digene® kit and tested for the presence of HPV DNA by two techniques in parallel, i.e., PCR using PGMY consensus primers for all HPV types and the Digene HPV test (Hybrid Capture 2 (HC2) Probe B for high-risk (hr) types. Genotyping was done on all HPV positive samples using the Roche reverse line blot assay. Results: HPV infection was detected in 91/1300 (7%) samples by PCR and 110/1300 (8.4%) samples by HC2. Genotyping identified 20 high-risk and 11 low-risk types. HPV16 was the commonest high-risk type (3%) followed by HPV52 (1.2%) and HPV51 (0.8%). Among low-risk types, HPV62 was the commonest (0.8%), followed by HPV84 and HPV89 (0.5% each). Multiple infections were found in 3% of the HPV positive samples. Conclusion: A wide spectrum of HPV genotypes is seen in this young population. Knowledge about HPV types prevalent in communities in different regions of India would be useful in devising the optimum strategy for cervical cancer prevention. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
